Earnings

CollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate

Sep 30, 2026 · 05:33 PM ET· updated 54m ago

CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(0.24) by 604.17 percent. This is a 26.52 percent increase over losses of $(2.30)

Why It Matters

CollPlant lost much more money than experts thought it would. When a company misses like this, watch if they explain what went wrong.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CLGN3.76

-0.04 (-0.92%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.